Study of VYD2311 for the Prevention of COVID-19
← catalyst calendarNCT07298434 · readout ≤ 11 d
Sponsored by Invivyd, Inc. (industry) · IVVD — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
1,770estimated
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-08 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19
Interventions
- Drug: VYD2311-SD
- Drug: VYD2311-MD
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFRT-PCR-confirmed symptomatic COVID-19 through Day 90
measured 90 days
Permalink · IVVD's whole pipeline · Catalyst calendar · Every registered study · What changed